Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.07.037
Abstract: BACKGROUND Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-rechallenged therapy for EGFR-mutant non-small cell lung cancer (NSCLC) patients who acquired resistance showed moderate efficacy. Considering the high interrelation between EGFR and vascular endothelial growth factor/vascular… read more here.
Keywords: egfr; apatinib; resistance; cell ... See more keywords
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Sign Up to like & getrecommendations! Published in 2020 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2020.106858
Abstract: Increasing studies confirm that anti-angiogenesis can increase the effectiveness of immunotherapy. In this study, we found that an angiogenesis inhibitor apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression. Apatinib treatment… read more here.
Keywords: apatinib; expression; colon cancer; mice ... See more keywords
Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism
Sign Up to like & getrecommendations! Published in 2020 at "Saudi Journal of Biological Sciences"
DOI: 10.1016/j.sjbs.2019.11.036
Abstract: Objective To investigate the effect of apatinib when treating advanced gastric cancer (GC) as well as the mechanism of preventing infection. Methods: From January 2017 to December 2018, 100 advanced GC patients had failed to… read more here.
Keywords: apatinib; infection; group; effect ... See more keywords
Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis.
Sign Up to like & getrecommendations! Published in 2020 at "Experimental cell research"
DOI: 10.1016/j.yexcr.2020.111934
Abstract: OBJECTIVE Vascular permeability contributes to disease progression and drug resistance in hematological malignancies, including AML. Thus, targeting angiogenic signaling is a promising treatment strategy, especially for relapsed and resistant AML. The aim of this study… read more here.
Keywords: apatinib; angiogenesis; targeting vegfr2; cytotoxicity ... See more keywords
Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-59746-1
Abstract: Transcatheter arterial embolization (TAE) plays an important role in clinical liver tumor therapy. However, hypoxia after TAE limit the medium-long term efficacy of TAE. Thus, in our study, we explored the treatment effect and mechanism… read more here.
Keywords: apatinib; arterial embolization; iodized oil; growth ... See more keywords
Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz283.035
Abstract: Abstract Background Gastrointestinal stromal tumors (GISTs) patients (pts) who develop resistance to imatinib and sunitinib have few therapeutic options. Apatinib is a multiple tyrosine kinase inhibitor and targetsVEGFR2, PDGFRβ and c-Kit, which is effective in… read more here.
Keywords: apatinib; trial; efficacy safety; imatinib sunitinib ... See more keywords
Efficacy of Low-dose Apatinib in Advanced HER2-negative Breast Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz338.103
Abstract: Abstract Background HER2-negative breast cancer patients have fewer treatments than HER2-positive patients, especially in patients with metastatic breast cancer, Apatinib is a small-molecule tyrosine kinase inhibitor that selectively targets VEGFR-2. Previous studies have shown that… read more here.
Keywords: negative breast; her2 negative; apatinib; breast cancer ... See more keywords
A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz438.022
Abstract: Abstract Background Hepatocellular carcinoma (HCC) is the most common malignancy with high rates of recurrence and metastasis after radical resection. Vascular invasion, including portal vein tumor thrombus (PVTT) and microvascular invasion (MVI), and microsatellite lesions… read more here.
Keywords: apatinib; recurrence; shr 1210; therapy ... See more keywords
Effective apatinib treatment of pleomorphic liposarcoma
Sign Up to like & getrecommendations! Published in 2017 at "Medicine"
DOI: 10.1097/md.0000000000007771
Abstract: Rationale: Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. Patient Concerns: We presented an 81-year-old Chinese woman with advanced… read more here.
Keywords: effective apatinib; pleomorphic liposarcoma; apatinib; apatinib treatment ... See more keywords
Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma
Sign Up to like & getrecommendations! Published in 2017 at "Medicine"
DOI: 10.1097/md.0000000000008507
Abstract: Rationale: Pulmonary epithelioid hemangioendothelioma (P-EHE) is a rare tumor, with no established standard treatment. Overexpression of vascular endothelial growth factor receptor 2 (VEGFR-2) has been reported in some P-EHE patients. Apatinib, a new small molecule… read more here.
Keywords: epithelioid hemangioendothelioma; treatment; apatinib; pulmonary epithelioid ... See more keywords
Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000013924
Abstract: Rationale: For advanced non-small-cell lung cancer (NSCLC), targeted therapy and chemoradiotherapy are recommended as the first-line treatment. For patients with a performance status (PS) score over 2 and without gene mutation, however, only supportive treatment… read more here.
Keywords: gene type; apatinib; gene; wild gene ... See more keywords